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Abstract !
Prostate cancer (PCa) is the most common malignancy in men. Aggressive prostate 
tumours must be identified, differentiated from indolent tumours, and treated to ensure 
survival of the patient. Currently, clinicians use a combination of multi-parametric 
magnetic resonance imaging (mpMRI) contrasts to improve PCa detection. While these 
techniques provide very good spatial resolution, the specificity is often insufficient to 
unequivocally identify malignant lesions.  
Utilizing specialized MRI hardware developed for sensitive in-vivo detection of sodium, 
this work has investigated differences in sodium concentration between healthy and 
malignant prostate tissue. Patients with biopsy-proven PCa underwent conventional 
mpMRI and sodium MRI followed by radical prostatectomy. Subsequent whole-mount 
histopathology of the excised prostate was then contoured according to Gleason Grade, a 
radiological assessment of tumour stage and aggressiveness for PCa. Tissue sodium 
concentration (TSC) measured by sodium MRI was successfully co-registered with 
standard image contrasts from multi-parametric MRI and also with pathologist confirmed 
histopathology as the gold standard. 
This proposed method provides quantitative, in-vivo sodium information from cancerous 
human prostates. The results of this study establish the relationship between TSC and 
malignant PCa, which could prove useful in initial characterization of the disease and for 
active surveillance of indolent lesions.  !
Keywords !
Sodium (23Na), Prostate Cancer, Magnetic Resonance Imaging (MRI), Tissue Sodium 
Concentration (TSC) !!!!!!
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Chapter 1 
1 Introduction !
1.1 The Prostate Gland 
The prostate is a walnut-sized organ whose primary function is to produce fluids 
(prostatic fluid) associated with male reproduction. Prostatic fluid makes up 30% of 
semen, by volume, with the remaining 70% made up of spermatozoa and seminal vesicle 
fluid (1). The prostate is located directly below the urinary bladder and surrounds the 
location where the prostatic urethra and the ejaculatory ducts merge. A small amount of 
smooth muscle contained within the prostate aids with ejaculation, a secondary function 
for the prostate (2).  
 
Figure 1; Anatomy of the prostate gland. The peripheral zone (purple), central zone (red), 
transition zone (blue), and the anterior fibromuscular stroma (green), as well as the 
urethra (yellow) are shown. 
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Four zones define the prostate gland (Figure 1): central, transitional, anterior 
fibromuscular, and peripheral. The central zone (CZ) surrounds the ejaculatory ducts and 
makes up roughly 20% of the prostate by volume. The transitional zone (TZ) surrounds 
the proximal urethra and comprises 5% of prostatic volume. The peripheral zone (PZ) 
comprises 70% of the prostate by volume and surrounds the CZ, TZ as well as the distal 
urethra. Finally, the anterior fibromuscular zone (AFS) comprises 5% of the prostate and 
is comprised of only fibrous and smooth muscle elements (3). 
1.2 Prostate Cancer 
1.2.1 Statistics 
Prostate Cancer (PCa) is the most common malignancy for men in Canada, with one in 
eight diagnosed overall. In 2014, there were 23,600 new cases of PCa in Canada alone 
with 40% of men diagnosed between the ages of 60-69. Men who are diagnosed with PCa 
have a relatively low probability (1 in 28) of death but also experience a diminished 
quality of life (4). Most cases of PCa (99%) are adenocarcinoma, which is a defined as 
neoplasia of epithelial tissue with glandular origin, glandular characteristics, or both (5). 
Between 2001 and 2009, the mortality rate of PCa declined significantly, this is most 
likely due to improved treatment options and/or the introduction of the prostate-specific 
antigen (PSA) test but studies reported conflicting results (6,7). 
1.2.2 Symptoms 
Though early forms of PCa do not present symptoms, advanced stage symptoms range 
from: prostatic bleeding, blood present in semen, bone pain, and urinary obstruction. 
Patients could misinterpret lower urinary tract disease as urinary obstruction, which 
occurs due to benign prostatic enlargement. 
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1.2.3 Screening 
According to the National Comprehensive Cancer Network (NCCN) practice guidelines, 
asymptomatic PCa suspicions begin with an abnormal digital rectal exam (DRE). In this 
process, a physician will palpate the prostate through the rectum to determine any 
irregularities. Regardless of the outcome of other metrics, symptomatic patients receive a 
bone scan to test for metastases. The NCCN also recommends the use of the PSA test, 
which as many studies have concluded, is a controversial method (8). 
Centres that use the PSA test as a risk evaluation tool (among other metrics) set a 
threshold at which the patient should undergo biopsy. The level of antigen present in the 
blood stream in order for a patient to undergo biopsy varies. While there is a correlation 
between increasing risk of PCa and increasing PSA levels, there is no lower limit, which 
eliminates the risk altogether (9). PSA thresholds set at 3 and 4 ng/ml had false positives 
rates of 19.8% and 11.3%, respectively (10,11). The Prostate Cancer Prevention Trial 
(PCPT) studied nearly 19,000 men between October 1993 and June 2003 in the United 
States (12). The trial reported findings of PCa for 15% of men with a PSA < 4 ng/ml and 
normal DRE, 30-35% of men with 4 ng/ml < PSA < 10 ng/ml, and 67% of men with a 
PSA > 10 ng/ml (13,14).  
Patients with positive PSA test results are scheduled for further screening techniques, 
including prostate biopsy. Prostate biopsy is a procedure in which twelve core samples of 
prostate tissue are systematically acquired by needle biopsy from the rectum. This 
procedure is often aided by image-guided techniques such as ultrasound or magnetic 
resonance imaging (MRI).  Possible side effects of prostate biopsy include hematuria 
(blood present in urine), infection, hospital admission, and in some cases death. An 
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observational study of 1000 men who underwent prostate biopsy noted that patients had 
experienced side effects such as: hematuria (31%), infection (0.9%), hospitalization 
(2.1%), and death (0.2%) (15).  
Overdiagnosis is a term used when disease is correctly detected but would not cause 
noticeable symptoms or death and is an inevitable consequence of screening for disease. 
The prevalence of overdiagnosis in PCa varies according to the frequency of screening, 
threshold of the PSA test used, patient age, number of core samples taken, and disease 
risk (16). It has been shown that 40-56% of men screened who received a diagnosis of 
PCa can be attributed to overdiagnosis (15). While there has been a reduction in PCa 
mortality from 38% in 1995 to 22% in 2006, quality of life has become a relevant 
concern related to the problem of benefit versus harm.  
1.2.4 Grading & Staging 
Gleason Grading 
Donald F. Gleason established the gold standard grading system for PCa in 1966. 
Appropriately named the Gleason system; it has been amended twice in 1974 and 1977 
by Gleason himself (17). The system is based upon low-power, microscopic observation 
of morphological features of prostate tissue classified by Gleason. All tumours are judged 
to fit within 5 categories, representing different states of complexity in morphology. A 
tumour is graded depending on the most prevalent (primary) and the second most 
prevalent (secondary) observed Gleason Grade. The combination of these two gradings is 
called a Gleason Score (primary grade + secondary grade = Gleason Score) (18). Many 
reports have confirmed the significance of Gleason Scoring and outcome after no 
treatment (19), treatment with radical prostatectomy (20), and radiation therapy (21).  
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Prostatic Intraepithelial Neoplasia (PIN) describes a lesion that, although isn’t cancerous, 
could be a possible precursor to malignancy (9). PIN is most easily described as the 
presence of prominent nuclei within an existing duct structure. The similarities between 
PIN and prostatic carcinoma include: increased severity and incidence with age and 
prominence within the PZ of the prostate (22). Benign Prostatic Hyperplasia (BPH) is the 
formation of benign nodules within the prostate due to an increase in cell proliferation. In 
some cases these nodules can obstruct the urethra, leading to painful urination (8). 
A Gleason Grade of 1 (Figure 2(1)) describes tissue that is uniform, comprised of 
separate, closely packed glands. Gleason Grades 1 and 2 are very well-differentiated and 
in most cases today would be considered atypical adenomatous hyperplasia by 
immunohistochemistry (18). Grades 1 and 2 patterns diagnosed from needle core biopsies 
were given a higher grade at radical prostatectomy, and also had poor reproducibility; 
therefore they are rarely assigned (23).  
Figure 2; Gleason Grades 1-5, where Gleason Grade 1 are least aggressive and Gleason 
Grade 5 are most aggressive. With increasing Gleason Grade, prostate gland structures 
are decreasingly differentiated. As Gleason Grade progresses, gland patterns shift from 
well defined units to fused or poorly defined units with no internal lumina. 
1! 2! 3! 4! 5!
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Gleason Grade from biopsy is reliable and significant for Gleason Grade 3, which 
represents the most common Gleason patterns reported from biopsy. In Grade 3, gland 
units are typically smaller than Gleason patterns 1 and 2; infiltration between benign 
glands is common (Figure 2(3)). In Gleason 3, gland units are still distinguishable with a 
defined border, a distinction that separates Gleason 3 from Gleason 4.  
In Gleason 4, a new tissue characteristic is introduced. Cribriform structures are 
described as large irregular glands without recognizable lumina. Gleason 4 could also 
present as fused, ill-defined glands with poorly formed glandular lumina (Figure 2(4)). 
One consideration pathologists need to beware of is tangential sectioning, where the 
biopsy needle’s trajectory is such that it bisects the glands at an angle that distorts the 
appearance of the gland units. Tangential sectioning creates the impression of ill-defined 
glands with inconspicuous lumina that could lead to a false-positive diagnosis as Gleason 
4 (24). 
The most aggressive pattern in the Gleason grading system is Gleason 5, where there is 
no longer any glandular differentiation (Figure 2(5)). In pattern 5, the cribriform 
structures from Gleason 4 are upgraded with central comedonecrosis. Comedonecrosis is 
the presence of necrotic cells within the luminal space of the gland and/or karyorrhexis, 
where the nucleus of a dying cell is distributed irregularly throughout the cytoplasm 
(24,25).  
The distinction between Gleason Grade 3 and 4 is an extremely important one. This is a 
threshold that the NCCN (9) and Cancer Care Ontario (CCO) (26) has set to determine 
which patients will undergo active surveillance (these patients will have routine follow-
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up examinations at set time intervals) and those patients who require immediate treatment 
(these patients will undergo treatment procedures such as radical prostatectomy, 
brachytherapy, and chemotherapy). By correctly distinguishing patients into therapy 
groups, patients can be spared psychological and physical pain from unnecessary 
treatment; as well as save an estimated $100 million in healthcare costs per annum in 
Canada alone (27). 
Staging 
In order to deliver a clear diagnosis; clinicians use a staging system to distil all prognostic 
factors into a single classification. The most commonly used staging system for prostate 
cancer is the American Joint Committee on Cancer (AJCC) tumour, node, and metastasis 
(TNM) system. Further subcategories of each classification are used to describe the 
cancer in detail (8). 
To describe the size and invasion of the tumour, “T classification” is used.  
• T1: the tumour is not apparent by DRE nor visible by imaging 
• T2: the tumour is confined to the prostate gland 
• T3: the tumour extends beyond the prostatic capsule 
• T4: the tumour is fixed or invades adjacent structures 
To describe lymph node metastasis, “N classification” is used. 
• NX: lymph nodes were not assessed 
• N0: no regional lymph node metastasis 
• N1: metastasis present in regional lymph nodes 
Finally, if the cancer has spread past the lymph nodes, “M classification” is used. 
• M0: no distant metastasis 
• M1: distant metastasis 
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1.2.5 Cell Metabolism & Regulation 
The regulation of intracellular pH is important for cellular function; it plays a role in cell 
proliferation, invasiveness, drug resistance and apoptosis (28–30). Proliferative cancer 
cells in solid tumours increase anaerobic glycolysis to compensate for hypoxia due to the 
limited diffusion of oxygen across tissue (31,32). This increased anaerobic glycolysis 
leads to a reduction of tumour pH through increased lactate production and hypoxic 
adenosine triphosphate (ATP) hydrolysis. As a mechanism to prevent apoptosis, the cell 
will increase proton efflux, regulating intracellular pH (33). One of the systems used by 
cells to regulate pH is the Na+/H+ (NHE1) antiport, which is inherently coupled to the 
transport of Na+ ions across cellular membranes (34–36). This antiport facilitates the 
exchange of extracellular Na+ for intracellular H+. Its been shown that the NHE1 
exchanger could also play a role in initiation of cell growth and proliferation (37,38). A 
study by Rotin et al. demonstrated that human tumour cells lacking the NHE1 exchanger 
either lost or severely reduced their ability to grow tumours (30). An upregulation of the 
NHE1 antiporters is a mechanism used to cope with intracellular acidification, which in 
turn increases intracellular sodium concentration (30,36,39,40). Expression of the NHE1 
antiport has been observed to affect tumour cell migration through extracellular 
acidification (41). Tumour cells metastasize through the metastatic cascade, in which the 
cell migration step is dependent upon the degradation of the extracellular matrix through 
acid extrusion (42). Based on solid tumours, increased intracellular sodium levels would 
likely be expected as an inherent result of upregulated NHE1 (32). Cameron et al. 
showed that “…rapidly dividing cells had significantly higher sodium concentration than 
did the slowly dividing cells but significantly less sodium than did the tumor cells” (28). 
Intracellular sodium concentration ([Na+]in) is largely regulated by a combination of 
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NHE1 (influx) and Na+/K+ ATPase (efflux) and can vary by large amounts. Extracellular 
sodium concentration ([Na+]ex) rarely deviates from plasma concentrations, which is 
regulated by renal sodium exchange and tissue perfusion (28,39,40,43). Tissue Sodium 
Concentration (TSC) is a weighted average of the [Na+]in and [Na+]ex based on relative 
intracellular volume (IVF) and extracellular volume fractions (EVF). [Na+]ex is 
essentially kept constant at ~140 mmol/L with sufficient tissue perfusion (44), while 
normal [Na+]in is ~10-15 mmol/L (45–47).  A study by Langer et al. showed that EVF 
decreased from 68.8% to 52.1% while IVF increased in PCa when compared to normal 
prostate tissue (48). Assuming a constant [Na+]ex, an IVF of 46.2% and an EVF of 52.1%, 
[Na+]in can be calculated for a given TSC value. Intracellular sodium concentration is an 
indirect measure of cell malignancy and mobility (28,41). Therefore a non-invasive 
method capable of quantifying tissue sodium concentration could prove useful in 
assessing cancerous tissue.  
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1.3 Basics of MRI 
Magnetic Resonance Imaging (MRI) is a diagnostic modality that is unrivalled in its 
ability to produce excellent soft-tissue contrast images of biological systems high spatial 
resolution and with no ionizing radiation (49). Developed in the early 1970s, the number 
of clinical MRI units has grown to an estimated 25,000 with 266 systems installed in 
Canada (50). To produce contrast, MRI exploits the interaction of nuclear spins within an 
applied magnetic field. The most common nuclide utilized is the proton of the water 
molecule because of its high abundance in the body (80 mol/L), intrinsic nuclear spin of 
½ and large magnetic dipole moment. A fundamental physical property of nuclei, nuclear 
spin is a combination of contributions from both unpaired protons and neutrons.  Not all 
nuclei are observable by MRI; only those that possess a non-zero-spin value. When 
placed in a magnetic field, the magnetic dipole moments of non-zero-spin nuclei precess 
around the magnetic field direction and will preferentially align, to a small degree, with 
the magnetic axis. In the case of MRI, this axis exists along the bore of the magnet and, 
by convention, is denoted by the letter z in a Cartesian axis system. This creates a small 
net magnetization (M0) along the magnetic field direction. However, in the absence of a 
dominant magnetic field, the angles of the precession of spins with respect to the z-axis 
are randomly distributed resulting in no net magnetization. A particular nuclide precesses 
at a specific frequency within a uniform magnetic field, termed the Larmor frequency 
(ω0). The Larmor frequency of a nuclide is proportional to the strength of the field in 
which it is placed (B0) and is given by 
ω0 = 2πγB0     (1.3.1) 
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where γ, the proportionality constant, is called the nuclear gyromagnetic ratio measured 
in Hertz per Tesla. The gyromagnetic ratio is unique for each nuclide. Clinical MR 
systems vary in magnetic field strength, measured in Tesla (T), from low-field  (0.2T) to 
high field (7T) systems. Most MRI scanners in operation today utilize a field strength of 
1.5T but in recent years there has been a large increase in the number of higher field 
strength magnets (3-7T) (50). Higher field strengths have the advantage of an increased 
signal to noise ratio (SNR) for MRI associated with greater magnetization and higher 
Larmor frequencies. This can allow for shorter imaging times at higher spatial resolution 
but comes at the price of higher equipment costs, greater sensitivity to field 
inhomogeneities, potential tissue heating and electromagnetic coupling between transmit 
and receive structures (51). 
An MRI produces signal by perturbing the bulk magnetization of tissue with radio 
frequency (RF) waves at the Larmor processional frequency of protons. As the excited 
magnetization relaxes back to equilibrium, it emits RF energy, which is also at the 
Larmor frequency. The RF power is often applied by a dedicated transmit coil. This is a 
tuned RF circuit, which is resonant at the Larmor frequency of the nuclide of interest. To 
detect the relaxation of the magnetization, a separate proximal RF receive coil, resonant 
at the same Larmor frequency can also be used for increased local signal sensitivity. 
Excitation of the tissue magnetization is accomplished by short pulses of RF power 
applied to the transmit coil. Before an RF pulse is applied the bulk magnetization is 
oriented longitudinally aligned along the z-axis. A 90˚ RF pulse will flip the longitudinal 
magnetization into the transverse (x-y plane) reducing the longitudinal magnetization to 
essentially zero. The magnetization then relaxes back to the longitudinal equilibrium state 
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through different mechanisms. Spin-spin (T2) and spin-lattice (T1) are the two 
predominant relaxation features that affect the excited magnetization immediately 
following an RF excitation pulse.  
Spin-lattice relaxation represents the loss of energy from the spin system to the 
surrounding lattice (environment). This exchange of energy is a result of local 
fluctuations in the magnetic field due to interactions of tumbling molecules.  Protons in 
water molecules are tumbling in the environment of these fluctuating magnetic fields and 
can gain or lose internal energy as a result of these electromagnetic fluctuations they 
experience. For example, a larger number of magnetic fluctuations at or near the Larmor 
frequency produce more effective spin-lattice relaxation. This exchange of energy 
governs how quickly the tissue re-magnetizes after application of an RF excitation pulse 
and how quickly repeated RF pulses can be applied. The longitudinal magnetization, 
Mz(t), asymptotically relaxes back to the thermal equilibrium value as Mz(t) = M0(1-e-t/T1), 
where the exponential time constant, T1, is the spin-lattice relaxation time governing this 
process. 
Spin-spin relaxation is due to the dephasing of the ensemble of spins from their coherent 
precession after RF excitation to a nearly uniform distribution in the transverse plane. 
This dephasing occurs due to slight differences in precessional frequencies for individual 
spins arising from intrinsic magnetic field inhomogeneities. Apparent magnetic field 
inhomogeneities experienced by nuclei in molecules are linked to the molecular size and 
mobility of the molecules. Small, fast tumbling molecules, such as free water effectively 
average out the magnetic field inhomogeneities, resulting in an apparently relatively 
homogeneous local field, so that very little dephasing of the spins and longer T2 (spin-
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spin relaxation) times are observed. Nuclei in large, slow tumbling molecules such as fat 
experience a relatively static magnetic field inhomogeneity, leading to more dephasing of 
the transverse magnetization and faster signal decay (shorter T2 times) (49). The receive 
RF coil detects an oscillating signal at the Larmor frequency with an exponentially 
decaying amplitude whose exponential time constant is T2*, the effective spin-spin 
relaxation time. T2* characterizes the apparent relaxation time due to the inherent sources 
of magnetic field inhomogeneity mentioned above as well as external sources of 
inhomogeneity due to imperfect magnetic field shimming and magnetic susceptibility 
effects related to air/tissue interfaces and iron-containing blood. T2* is always shorter than 
T2. 
T1 and T2 relaxation times are fundamental properties associated with a particular nuclide 
for a given tissue and are observable as a bulk property. Knowledge of these relaxation 
times are important for optimizing the imaging parameters of a pulse sequence to garner 
the most signal from a particular sample or to optimize the image contrast between 
healthy and cancerous tissue.  
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1.4 Sodium MRI 
1.4.1 Basics of Sodium MRI 
As mentioned above, any nuclide that possess a non-zero spin value can, in principle, be 
detected using MRI. Of particular interest are sodium (23Na) nuclei, which possess a !!  
spin value. 23Na MRI is technically difficult because of low sodium concentration in the 
body (~90 mmol/L) verses the concentration of protons (80 mol/L), its low gyromagnetic 
ratio (1/4 that of protons), and its !! spin. Sodium MRI is often referred to as 23Na MRI 
and despite its lack of success during early research (52), it has become more feasible in 
recent years due to advancements in high-field MRI hardware, pulse sequence software, 
and widespread implementation of multi-nuclear MRI systems (53–56).  
1.4.2 Bi-Exponential Decay of Sodium 
23Na MRI is technically difficult due to the limited endogenous sodium concentration and 
rapid spin-spin relaxation times; however, the very short T1 relaxation time supports 
shorter repetition rates (TR), leading to faster signal acquisition and reduced imaging 
times. Even with TR set to three times the T1 of 23Na (to allow for quantification of TSC 
without T1 corrections), ten RF excitations are possible in one second. In addition to low 
endogenous concentration, 23Na MRI is challenging due to the intrinsic !! spin value of 
sodium nuclei. This higher spin value, compared with that of the proton, results in bi-
exponential T2 relaxation (two distinct components to the exponential signal decay) for 
sodium (“long component”: 20-30ms and “fast component”: 1-2ms). Sodium nuclei can 
have four distinct energy levels (Zeeman energies) in a magnetic field, -!!, -!!, !!, and !! and 
can transition between each of them. A change between adjacent energy levels is called a 
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single quantum transition, but changes between other levels are possible, double or triple 
quantum transitions. Normally in an unrestricted watery solution containing sodium, all 
transitions are single quantum, and have the same energy. In tissue, the movement of 
sodium is more restricted - particularly within cells.  This alters the relative amount of 
short versus long component T2 decay, which is observed. For sodium imaging of tissue, 
the long and short components comprise approximately 60% and 40% of the signal, 
respectively. For quantification of TSC, a short acquisition delay (TE) is required to 
observe both the short and long component T2 decay, which helps to reduce T2 losses 
(52).  
1.4.3 Separating Signal Components 
Distinguishing between intracellular sodium and extracellular sodium is essential to the 
success of 23Na MRI in biomedical research. Intracellular sodium reflects the stability of 
the cellular membrane, as well as the state of cellular metabolism (57), while extracellular 
sodium is usually fixed by perfusion. The triple quantum filtered (TQF) technique has 
shown promise as an effective method of separating the signal from these two 
compartments (58–60). TQF attempts to suppress the extracellular component of the 
signal through manipulation of the bi-exponential decay due to the quantum transitions 
between energy states. The TQF approach assumes that the long and short T2 components 
of the signal are specific to the extracellular and intracellular compartments, respectively. 
The experimental difficulty with TQF lies in the low SNR, which leads to longer scan 
times and reduced resolution. There have also been reports of unwanted extracellular 
sodium significantly contributing to TQF signals (58,61), therefore caution with this 
technique is warranted. Bi-exponential weighted 23Na imaging is a promising technique 
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that utilizes both spin-density weighted and single-quantum-filtered imaging. It offers 
compartment separation without the drawbacks of low SNR and longer scan times as in 
TQF (62). The method uses a single-quantum-filtered image, which contains mainly 
signal from mono-exponentially decaying sodium nuclei and a spin-density weighted 
image, which contains signal from all sodium ions. The single-quantum-filtered image is 
subtracted from the spin-density image to produce contrast mainly from the intracellular 
compartment. 
To obtain absolute sodium concentration information, calibration phantoms must be 
employed. A large volume phantom of concentration 100-150 mmol/L is needed to assess 
the RF coils, as well as two or more reference phantoms ranging in concentration from 
20-150 mmol/L. The reference phantoms were integrated into the RF receive coil. These 
phantoms both allow absolute sodium concentration measurements as well as provide 
fiducial markers for registration purposes. 
1.4.4 Disease Applications 
 Sodium MRI can detect changes in metabolism of tissue as well as cellular membrane 
integrity. Healthy cells maintain a constant 23Na gradient across the cellular membrane. A 
disruption of the cell membrane or impaired energy metabolism will result in an increase 
of [Na+]in (57). Significant 23Na changes can be seen in myocardial infarction (63), stroke 
(44), and cancer (64,65). 
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Sodium levels have been shown to increase after stroke induced in rats as determined by 
flame spectrometry of punch samples (66); these findings have since been confirmed with 
23Na MRI (67,68). Sodium MRI has also been shown as a possible tool to monitor 
therapy that causes cell death such as chemotherapy. A xenograft animal model of PCa 
(69) as well as breast cancer patients undergoing chemotherapy (70) reported a 
significant decrease in TSC with a decrease in lesion size.  
Imaging cancer with 23Na MRI has been a growing area of research due to the 
fluctuations of [23Na]in  in cells with increased mobility and proliferation (30,36–40). 
Sodium MRI studies have reported an increase in TSC of 50% in both brain and breast 
cancers compared to normal tissue (64,65), and a doubling of TSC in low-grade glioma 
(71). 23Na MRI has been employed to measure sodium in the healthy human prostate (72–
74) and the cancerous mouse prostate (75) but TSC values have yet to be measured in a 
cancerous human prostate. The purpose of this thesis is to examine the potential for the 
use of 23Na MRI in the clinic as a non-invasive tool to aid clinicians in PCa treatment 
stratification.!!
!
!
!
!
!
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Chapter 2 
2 Hardware Construction and Testing !The!contents!of!this!chapter!were!previously!published!by!Farag!et#al.,!for!which!I!was!second!author!(1).!
2.1 RF Hardware 
To acquire signal from sodium nuclei two pieces of RF hardware were designed and built 
in the 2nd Floor Imaging RF Engineering Laboratory at the Robarts Research Institute. 
The first was a birdcage transmit-only coil (designed and built by Adam Farag (1)) with 
an asymmetric cross section used to excite the sodium nuclei at their specific Larmor 
frequency (Figure 3a). 
 To achieve this, the quasi-elliptical cross-section of an MR 750 GE 3T was determined 
and a volume resonator large enough for a human torso was constructed for RF excitation 
of the sodium magnetization. The top half of the resonator assembly is detachable from 
the bottom to facilitate easy patient access. The resonator itself was constructed of 16 
copper tubes functioning as rungs held in place by two Delrin® plastic end rings 
machined to match the elliptical cross sections of the usable bore volume. The 
asymmetric coil was tuned to resonate at the Larmor frequency of sodium nuclei at 3T 
(33.78 MHz) according to values calculated in Farag et al. (1). 
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Figure 3: a) The transmit-only asymmetrical birdcage coil. b) The Mark-3 endorectal 
(ER) surface receive-only sodium coil. Both resonators were tuned to the Larmor 
frequency of sodium at 3 Tesla (33.78 MHz). 
The second piece of RF hardware designed and constructed was a rigid endorectal (ER) 
surface coil to receive signal from the sodium nuclei at their specific Larmor frequency 
(constructed by Adam Farag and myself (1)) (Figure 3b). A rigid design was chosen for 
simplicity and to facilitate co-registration of 23Na MRI and mpMRI imaging data. 
Multiple versions of the probe were designed and constructed before the final design was 
chosen. I coated all the probes with biocompatible sealant (MS151 MED, Masterbond, 
NJ), which acted as a fluid-resistant seal as well as an additional layer of heat and 
electrical insulation. 
 
65!cm!
43!cm! ! 18#cm 
a! b!
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The Mark-1a ER probe contained a dual-tuned RF loop for both 1H (127.74 MHz) and 
23Na (33.78 MHz) while the Mark-1b contained only a single tuned RF loop for 23Na 
imaging. Adam Farag manufactured the identical shells of the Mark-1a/b endorectal coils 
from polycarbonate using 3D printing. The ER probe consisted of two separate volumes; 
the proximal section inserted into the subject contained the RF circuit loop, while the 
stem/base section housed the wires connecting the circuit with the balun and matching 
circuitry in an adjoined external box. The Mark-1 probes had insufficient internal volume 
within the proximal end to house reference calibration vials, which are essential for 
absolute TSC measurement; therefore a larger Mark-2 version was constructed. 
The single tuned (23Na-only) Mark-2 endorectal coil was 3D printed by Adam Farag from 
ABS-M30 by Fotus® with all essential sections incorporated into one solid piece. The 
proximal end housed the RF circuit loop as well as three-one-millilitre reference 
calibration vials (which I constructed and implemented) containing 30, 90 and 150 
mmol/L concentrations of NaCl in water. The stem section housed the wires connecting 
the RF loop and the balun and matching circuits, which were contained within the distal 
end of the probe. When inserted, the rigid, straight-stem design of the Mark-1 and -2 was 
determined to interfere with the MR bed and affected the anatomy of the patient.  
To resolve the interference of the probe and MR bed and improve patient comfort, a third 
and final single tuned (23Na-only) probe was constructed (Mark-3). While the Mark-3 ER 
coil contained identical RF circuitry to the Mark-2, the difference between the Mark-2 
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and -3 was the incorporation of a 45˚ bend in the stem section and the ability to separate 
the proximal/stem section from the distal section. 
2.2 Imaging Phantoms !
To test and calibrate the RF hardware, five phantoms were constructed:  
1) a prostate-sized saline phantom of diameter 2.9 cm and NaCl concentration of 
154 mmol/L, used for SNR and B1 measurements of the endorectal probes,  
2) a hollow torso phantom of diameter 34.3 cm, used for loading the asymmetric 
birdcage for B1 measurements, 
3) a large cylindrical saline phantom of diameter 27.4 cm and NaCl 
concentration 154 mmol/L, used for mapping the B1 field within the 
asymmetric birdcage,  
4) a small cylindrical saline phantom of diameter 15 cm, used for mapping the 
3D sensitivity profile of the endorectal probes by submersion,  
5) a body-tissue-equivalent homogenous phantom, used in specific absorption 
rate (SAR) measurements of the endorectal probes.  
Imaging parameters for all phantoms can be found in Farag et al. (1). 
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2.3 Specific Absorption Rate Measurements 
The specific absorption rate (SAR) surrounding the endorectal probes was measured to be 
within acceptable levels, so not as to increase the temperature of surrounding tissue by 
more than 1˚C (2). This was measured using a body-tissue-equivalent homogenous 
phantom filled with hydroxyethyl cellulose (HEC) gel with electrical conductivity 
matching that of human tissue (0.27 S/m). Six individual optically coupled temperature 
transducers were placed on the probes, while two were inserted into the gel near the 
probes. The temperature transducers had a precision of 0.1˚C and their values were 
recorded at a frequency of 10 Hz for the duration of the imaging time. 
 
2.4 Image Processing 
The raw 23Na data were imported into Matlab (Mathworks, Natick, MA), where a k-space 
Gaussian filter (34 × 34, SD: 9) was applied before Fourier transformation. All 23Na 
image sets of 10 NEX were registered together using the three reference calibration vials 
as fiducials. The images were then averaged together to improve SNR; image sets with 
significant motion during acquisition were discarded. The averaged in-vivo volumes were 
then sensitivity corrected using a saline phantom volume, acquired with the 23Na 
endorectal coil submersed in the small cylindrical phantom with a diameter of 15 cm. 
23Na calibration data collected from this phantom used acquisition parameters identical to 
those used for the in-vivo 23Na data collection. Calibration of the ER RF surface coil’s 
receive profile was carried out using the method described in Axel et al. (3). To obtain 
absolute TSC values from the 23Na data, the known sodium concentrations of the vials 
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were plotted against average signal intensity values for the regions of interest (ROI) 
corresponding to the internal calibration vials. The tissue sodium concentration was 
calculated from 
!"# = ! !!!!! !                      (2.6.1) 
where, ST and SPh were the signal within a voxel in the tissue and small, cylindrical, 
saline phantom data, respectively. The quantity, U, is the slope acquired from the plot of 
signal intensity versus sodium concentration. Eq 2.6.1 is adapted from Wetterling et al. 
(4). The TSC uncertainty (ETSC) in each voxel was calculated according to Eq 2.6.2, 
where SNRT and SNRPh are the SNR in each voxel of the tissue image and phantom 
image, respectively. The parameter, δU, represents the uncertainty in determination of the 
slope, U. 
!!"# = !!"#! ! + !!"#!! ! + !"! ! ∗ !"#           (2.6.2) 
!
!
!
!
!
!
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Chapter 3 
3 Manuscript For Submission to Radiology !
Title: In-Vivo Sodium MRI of Prostate Cancer: Correlations with Gleason Grade 
Using Whole Mount Pathology 
3.1 Introduction 
One in seven men will develop prostate cancer (PCa) in their lifetime and most of these 
men will die with this disease, rather than as a result of it (1). Since the introduction of 
the prostate specific antigen (PSA) screening test, there has been a concern regarding 
overdiagnosis of clinically insignificant disease and therefore over-treatment (2–4). 
Overdiagnosis has been shown to negatively affect the quality of life of patients as well 
as being an economic burden on the healthcare systems (5). Diagnosis involves ranking 
specific PCa lesions according to Gleason Grade, the gold standard scale from one to five 
that is based on the differentiation of prostate gland units as scored by a pathologist on 
routine hematoxylin and eosin (H&E) microscopy. The Gleason Score, a combination of 
the primary and secondary grade present, is inherently related to tumor aggressiveness 
and the strongest prognostic and predictive factor in the disease and therefore is an 
essential assessment tool for guiding treatment plans (6–8). Urologists use transrectal 
ultrasound-guided biopsy cores to estimate Gleason Score for patient-specific treatment 
planning. Unfortunately, the biopsy only samples approximately 0.2% of the prostate and 
carries an approximate 30-40% risk of under sampling clinically significant foci of 
prostate cancer (9–11). The use of an alternative imaging-based method for estimation of 
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tumor grade would be a significant benefit. Non-invasive identification of potentially 
high-grade foci in the gland could be used to direct prostate biopsy or guide focal 
treatment approaches. Early in the treatment pipeline, accurate determination of the 
Gleason Score is essential to place patients in the proper treatment schemes according to 
tumor grade (for example, active surveillance for men with low grade, low volume 
lesions) in order to optimize patient outcomes and the use of health care resources. 
Multi-parametric magnetic resonance imaging (MRI) is emerging as a method to improve 
non-invasive PCa grading (12). Currently, clinicians use a combination of multi-
parametric MRI including T2-weighted, diffusion-weighted, and dynamic contrast 
enhanced imaging to improve PCa detection (13,14). 1H contrast-enhanced imaging 
exploits vascular volume and cellular organization changes through uptake of a 
gadolinium contrast agent. While these techniques provide high spatial resolution, the 
specificity is often insufficient to localize malignant lesions and assign a tumor grade. In 
addition, current mpMRI interpretation relies on qualitative suspicion scores (PiRADS 
scale), which are subject to inter-observer variation and require expert reading skills (15).  
Thus an imaging test that could provide complimentary information about the location 
and grade of intraprostatic cancer foci would be valuable.  
Sodium (23Na) MRI has been shown to reveal important information about biochemical 
and physiological processes within tissue. The tissue sodium concentration (TSC) in 
normal tissue is a sensitive indicator of cellular integrity and energy metabolism (16–18). 
TSC is a weighted average of the intracellular ([Na+]in) and extracellular sodium 
concentrations ([Na+]ex), based on relative intracellular volume (IVF) and extracellular 
volume fractions (EVF). [Na+]ex is essentially kept constant at ~140 mmol/L with 
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sufficient tissue perfusion (19), while normal [Na+]in is ~10-15 mmol/L (20–22). 
Therefore, the mechanisms in which TSC can vary are through extracellular volume 
changes (cellular organization, density) or through changes in intracellular sodium 
concentration (altered metabolism) (23,24). 
23Na MRI can be employed to obtain information about a combination of both 
intracellular and extracellular changes within tissue. Increased activity of the sodium-
proton (Na+/H+) antiport (25,26) and sodium-potassium (Na+/K+-ATPase) pump (17,27) 
in cells have been linked to tumor malignancy. A study by Cameron et al. (1980) 
concluded that slowly dividing cells had significantly lower [Na+]in than rapidly dividing 
cells, while tumour cells showed significantly higher [Na+]in than both slow and fast 
dividing cells (17). Previous studies have shown increased TSC in brain and breast cancer 
measured by MRI (18,24). While in-vivo endogenous sodium imaging has been 
demonstrated in both mouse (28) and human prostates (29,30), TSC has not been 
measured in human prostate cancer. We have previously developed a transmit-only 
receive-only (TORO) combination of an asymmetric birdcage coil and an endorectal coil 
that provided sufficient sensitivity to image 23Na nuclei in the human prostate (31). The 
purpose of the current study was to correlate in-vivo quantification of sodium with 
Gleason Score in patients with PCa.  In the work presented here, histologically identified 
prostate cancer was registered to in-vivo human sodium imaging data using a previously 
published and validated registration pipeline (32) that incorporates in-vivo 1H images 
acquired during the same MR exam as well as ex-vivo 1H images of the prostate obtained 
after prostatectomy. This study is the first to relate in-vivo MRI measured TSC of human 
prostate cancer with histopathologically confirmed Gleason Score. 
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3.2 Methods !
3.2.1 Patients 
Seven male patients (aged 61 ± 5) (Table 1) with biopsy-proven prostate cancer were 
recruited between June 2013 and November 2014 in conjunction with a multi-modality, 
image-guided prostate cancer study (IGPC-2) (32). In addition to the usual exclusion 
criteria for MR studies (implanted devices etc.), men were excluded from this study if 
they had prior therapy for PCa, use of 5-alpha reductase inhibitors (e.g. Finasteride or 
Dutasteride) within 6 months of the study start, a prostate volume greater than 68 cc 
(whole mount pathology limit), allergies to contrast agents and other administered agents, 
insufficient renal function, and a residual bladder volume greater than 150 cc. Patients 
were instructed to drink 30 mL of milk of magnesia the night before the MR exam and to 
fast 12 hours prior to the exam. 
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Category Patient 1 Patient 2 Patient 3 
Age 65 64 53 
Pre-Treatment Procedures    
Pre-biopsy PSA (ng/mL) 14.96 5.05 4.22 
Primary Pattern 3 3 3 
Secondary Pattern 4 4 4 
Overall Gleason Score 7 7 7 
Prostate Volume (cc) 45 30 25 
Clinical T-Stage cT2c cT2c cT1c 
Screening Bloodwork    
Creatinine (µmol/L) 76 64 92 
eGFR (ml/min/1.73m2) 95 116 79 
Urea (mmol/L) 5.1 3.9 6.9 
Residual Bladder Volume (mL) 78 224 165 
Post Radical Prostatectomy    
Primary Pattern 3 3 3 
Secondary Pattern 4 4 4 
Tertiary Pattern 5 none none 
Overall Gleason Score 7 7 7 
Pathological T-Stage pt3b pt3a pt2c 
Pathological N-Stage pn0 pno pn0 
Pathological P-Stage pmx pmx pmx 
Table 1: Clinically relevant information for three patients 
who completed the study, including pre-treatment 
procedures, screening bloodwork, and post radical 
prostatectomy procedures. 
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3.2.2 Sodium Imaging Exam Protocols 
High-resolution T2-weighted (T2-w) cube images (TE: 162 ms, TR: 2000 ms, FOV: 140 × 
140 mm, voxel size: 0.44 × 0.73 × 1.4 mm, flip angle: 90˚) were acquired using a 
standard inflatable 1H endorectal (ER) coil to allow for registration to histopathology.  
23Na imaging was performed using a custom-built ER receive-only RF coil and dedicated 
asymmetric transmit-only birdcage RF coil described in Farag et al. (31). The 23Na 
sequence was a broad-banded 3D efficient fast gradient recalled echo (bbefgre3D) with 
the following parameters, TE: 1.5 ms, TR: 80 ms, FOV: 140 × 140 mm, voxel size: 4.4 × 
4.4 × 6 mm, and flip angle: 85˚. For registration purposes, a set of 1H axial, T2-w images 
were acquired (TE: 139.2 ms, TR: 5300 ms, FOV: 140  × 140 mm, voxel size: 1.09 × 
1.09 × 3 mm, and flip angle of 90˚); the 1H axial T2-w images were taken with the 23Na 
ER coil inserted to provide morphological context for the 23Na images and to facilitate 
co-registration with a master set of 3D T2-w images. For each patient, topical anesthetic 
Xylocaine (2%) was applied before insertion of the ER coil. Three calibration vials 
containing 30, 90, and 150 mmol/L of NaCl within the 23Na ER coil were used to scale 
the sodium signal to absolute concentrations according to Farag et al. (31). 
 
3.2.3 Ex-Vivo Imaging Exam 
The prostate specimens were immobilized in a syringe of Christo-Lube MCG 1046 
(Lubrication Technology, Franklin Furnace, Ohio), which is an MR-invisible fluorinated 
lubricant that produces no MRI signal and also minimizes magnetic susceptibility 
artifacts at the tissue-prostate boundary. Excised prostates were prepared (described 
below) and imaged with both T1-weighted (T1-w) (TE: 2.34 ms, TR: 6.41, FOV: 140 × 
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140 mm, voxel size: 0.73 × 0.55 × 0.6 mm, flip angle: 15˚) and T2-w (TE: 114 ms, TR: 
2000 ms, FOV: 140 × 140 mm, voxel size: 0.73 × 0.44 × 0.6 mm, flip angle = 90˚) 
imaging contrasts using a 6-channel 1H carotid coil. These images assisted in accurate 
registration to histopathologic registration. 
 
3.2.4 Whole-Mount Histopathology 
Following radical prostatectomy specimens were marked with cotton threads soaked with 
a blue tissue dye doped with gadolinium. Three threads were pierced through the prostate, 
and seven threads were fixed to the surface to serve as fiducial markers, prior to ex-vivo 
MRI. The prostate midglands were sliced into ~4-mm transverse sections before paraffin 
embedding, leaving enough of the apex and base to be sagitally sliced for routine 
pathology analysis. Using a microtome, a 4-µm slice was obtained from each section and 
stained with H&E. The slides were then scanned at high resolution (0.5-µm isotropic 
resolution, 24-bit colour) using a bright-field slide scanner (ScanScope GL; Aperio 
Technologies, Vista, California) and subsequently contoured (Gleason Grading) and 
confirmed by a pathologist (32). Cathie Crukely, Dr. Mena Gaed and Dr. Jose Gomez-
Lemus contributed to histopathology. 
 
3.2.5 Registration  
Co-registration of image data was necessary due to the deformation of tissue, caused by 
differing geometries of the ER probes and the uncompressed nature of the tissue ex-vivo. 
Comparison of contoured histopathology and 23Na MRI data was achieved through a 
complex registration pipeline, involving several image contrasts. The registration pipeline 
is an important and unique part of this research study. Figure 4 outlines all image 
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contrasts used and their position in the pipeline. All registration was completed using 3D 
Slicer (Surgical Planning Laboratory, Harvard Medical School, Boston, Massachusetts), 
with a non-rigid, interactive, thin-plate spline (TPS) extension by Gibson, E. (2014) (33). 
Approximately 40 fiducial points were identified in pairs between two imaging volumes 
that were to be co-registered. Fiducials were placed on physiologically relevant ROIs, as 
well as patient-unique ROIs such as benign hyperplasia nodules and cystic spaces. In 
each registration, a reference volume and an input volume was chosen; where the 
reference volume remained unchanged and the input volume deformed according to the 
fiducial points. 
 
 
 Figure 4: The registration pipeline for all imaging data involved in the study. The 23Na 
volume, a) and body coil in-vivo T2-weighted volume, b) are registered to the endorectal 
in-vivo T2-weighted volume, c). The contoured histopathology, d) and the ex-vivo T1- and 
T2-weighted volumes (panels e) and f), respectively) are also registered to the endorectal 
in-vivo T2-weighted volume. 
 
a) b) c) 
d) e) f) 
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3.2.6 Statistical Analysis 
Once each 23Na MRI volume had been registered to corresponding histopathology, the 
pathologic contours on each slice were separated according to peripheral zone (PZ) and 
central/transitional zone (CTZ) as well as Gleason Score. In 3D Slicer, pathologic 
contours were imported as a separate mask from the remaining normal tissue and 
converted to scalar (gray scale) images. Each pathologic Gleason Score possessed its own 
unique intensity value, which were separated using a combined thresholding/ROI 
approach. This approach consisted of an initial manual selection of the bulk lesion, 
followed by an automated selection of the remaining pixels according to the desired pixel 
intensities. Within each histopathology image, Gleason Scores were separated into PZ 
and CTZ categories by manual segmentation on T2-w images. The anterior fibromuscular 
zone was not analyzed separately due to low 23Na signal and an inability to distinguish 
the zone on mpMRI. The remaining tissue in the histopathology images was designated 
‘normal tissue’ according to zone. The label maps were overlaid on the registered 23Na 
images and the overlapping TSC values within the contours of the lesions were recorded. 
All data were imported into GraphPad Prism (v6.0f, GraphPad Software, San Diego, 
California) and subsequently analyzed using a one-way ANOVA (Tukey test) to assess 
significance between grades.  
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3.3 Results 
Of the initial seven patients scanned with 23Na MRI, 3 were included in the analyses. In 
the remaining four patients; two were scanned with an ER coil that did not include 
reference standards (TSC could not be calculated); one patient did not return for radical 
prostatectomy surgery so histopathologic information was not available; and data from 
the fourth patient was excluded due to uncorrectable motion during image acquisition. 
Clinically relevant patient information is provided in (Table 1). Six different Gleason 
Grade groups were observed (Figure 6), according to the primary and secondary features 
present.  
 
Figure 5: A representative, unregistered, coloured map of the tissue sodium concentration 
(TSC) in one slice with its corresponding measurement uncertainty in percentage. Central 
and transitional zones are combined, with the peripheral zone outlined separately. 
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Non-rigid registration of the 23Na MR images to the contoured histopathology was 
accomplished to an accuracy of ~2 mm. The average TSC in normal peripheral zone 
tissue in all patients was measured to be 74.6 ± 6.7 mM (Figure 5). There was a 
statistically significant difference in TSC (Figure 6) between highly aggressive lesions (≥ 
Gleason 4+3) and moderately aggressive lesions (≤ Gleason 3+4) for Patients 1 and 2 
(p<0.0001); there were no Gleason 4+3 lesions present in Patient 3. The TSC between all 
Gleason Scores were significantly different (p<0.0005), with the exception of PIN vs. 
Gleason 4+3 in Patient 1 (p=0.3776), and PIN vs. Gleason 3 in Patient 2 (p=0.9892). 
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Figure 6: Three patients with biopsy proven prostate cancer underwent 23Na MRI to 
determine the TSC in different grades of tumour tissue. The bottom right panel shows a 
representative histopathology slice from one patient. All Gleason Grade groups are 
significantly different from each other (p<0.05) with the exception of PIN and Gleason 
4+3 in Patient 1 and PIN and Gleason 3 in Patient 2. Red bars highlight the threshold 
between active surveillance and active treatment (Gleason 3+4/Gleason 4+3). Error bars 
represent one standard deviation for all voxels of that Gleason Score. !
!!!
!* !NS ! NS * * * * * 
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3.4 Discussion & Conclusion 
We report the first in-vivo 23Na MR measurements from a cancerous human prostate. 
TSC levels were significantly increased in lesions with a high Gleason Score when 
compared to a low Gleason Score, and that of normal tissue within respective zones. 
Previously, we have demonstrated that TSC can be consistently measured with high 
signal-to-noise ratio (SNR) over the entire prostate (31).  
Dividing Gleason Score into qualitative low- (Gleason Score ≤ 3+4), and high-risk 
(Gleason Score ≥ 4+3) subgroups that correspond with treatment groups would establish 
the potential use for 23Na MRI in prostate cancer diagnosis. Patients who fall into the low 
category should be monitored under the active surveillance branch in the National 
Comprehensive Cancer Network’s (NCCN) guidelines (34). Patients in the high-risk 
category should undergo immediate treatment options within the NCCN’s guidelines. 
While Cancer Care Ontario (CCO) maintains that patients with a Gleason Score of 7 
should undergo active treatment, with the exception of select patients with low volume 
Gleason 3+4 PCa (8). More reliable noninvasive identification of biologically significant 
foci in the gland may enable targeted biopsy, focal therapy or focal dose escalation 
strategies (35–39). 
This study involved the development and application of advanced MRI hardware and 
imaging data analysis including high-resolution whole-mount digital histopathology, and 
the ability to register it in 3D to MRI data to a high degree of accuracy (~2 mm). The 
histopathology alone required an average of 70 hours of time per prostate from an 
experienced pathologist. The registration pipeline incorporated a novel automated 
registration technique with sub-millimeter accuracy (40) as well as a manual, interactive 
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TPS technique (32), both capable of 3D, whole-volume registration. Accurate registration 
and detailed histopathology is essential in determining that the TSC measured in a 
specific ROI is in fact a cancerous lesion as determined by gold-standard histopathology 
(Figure 7). Finally, the development of sensitive integrated TORO RF hardware for 
sodium imaging was a key enabler for this research (31). 
 
Figure 7: (a) high-resolution T2-weighted 1H Cube image, (b) an axially acquired 1H T2-
weighted image, (c) and the distribution of endogenous sodium concentration (d-f) with 
corresponding histology contours overlaid of an oblique slice through a prostate with 
biopsy-proven cancer. Grey contours represent prostatic intraepithelial neoplasia (PIN, a 
possible precursor to cancer); blue and red outlines are Gleason 3 and Gleason 3+4 
lesions, respectively. 
 
The current study shows that TSC increases with increasing Gleason Score in patients 
with prostate cancer. While we are unable to associate this correlation with specific 
cellular changes, it is likely due to cellular reorganization (volume changes) and 
increased intracellular sodium concentration (24). With increasing Gleason Score, 
cellular density increases, which leads to a decreased extracellular volume. The 
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extracellular matrix, if in constant exchange with the vasculature, maintains a sodium 
concentration of ~140 mM (41), while the intracellular sodium concentration in normal 
prostate tissue is on the order of ~10-15 mM (18). Assuming a constant [Na+]ex, a 
cancerous IVF and EVF of 46.2% and 52.1%, respectively, and a normal IVF and EVF of 
31.2% and 68.8%, respectively; [Na+]in can be calculated for a given TSC value (42). The 
average TSC increase across all patients from normal tissue to Gleason 3+4 was ~11 mM 
(16%); therefore the [Na+]in can be estimated to increase from 23.3 mM to 39.5 mM. 
Cancer cells have been shown to exhibit an increased metabolism, which supplies the cell 
with enough energy to support accelerated proliferation and enhanced motility (43). The 
caveats of this increased metabolism include an upregulation of the sodium-proton 
(Na+/H+) antiport (25,26) and an inhibited sodium-potassium (Na+/K+-ATPase) pump 
(17,27). As the tumor cell favors anaerobic glycolysis, the proton concentration within 
the cell increases reducing pH. Na+/H+ antiport is the major mechanism used to reduce 
the concentration of intracellular protons (16). As protons are pumped out decreasing the 
intracellular pH, the intracellular sodium concentration consequently increases. An acidic 
extracellular environment is also favored by the cancer cells, as it aids in cell motility 
(44) and invasiveness (45). The increased [Na+]in is not directly distinguishable from 
[Na+]ex but with assumptions of a constant [Na+]ex (19); and intracellular and extracellular 
volume fractions from PCa tissue (42) it is possible to indirectly estimate [Na+]in from 
TSC.  
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A limitation of the TSC measurement method is the inability to directly differentiate 
intracellular and extracellular sodium signal. As a result, we are unable to precisely 
measure the intracellular sodium concentration without knowing the relative 
compartment sizes within the tissue (assuming a known extracellular concentration). In 
principle, triple quantum filtering (TQF) could be used to discriminate signal from only 
the bound sodium ions but bound sodium is not exclusively found in the intracellular 
compartment (46,47). TQF techniques also have limited SNR and high sensitivity to B0- 
and B1-inhomogeneities making it a technically difficult prospect (48). One limitation of 
this study is the small sample size, which limits the ability to make predictions about the 
general population. 
Due to the limited sodium concentration in tissue, the spatial resolution of sodium MRI is 
modest compared to proton imaging (~5 mm3 vs. ~0.5 mm3). The pulse sequence used in 
this study was a bbefgre3D sequence that traversed k-space according to a Cartesian 
trajectory. 3D-Spiral pulse sequences, which are optimized for fast T2 relaxation and 
efficient coverage of k-space, could prove promising in increasing SNR. Further 
development in this area could potentially increase spatial resolution and/or reduce 
acquisition times. 
The inherent limitation of a surface ER coil is the receive profile, in which the signal 
requires sensitivity correction; due to the inhomogeneous receive profile. This issue is 
apparent not only in 23Na MRI but present in all prostate MRI (including 1H MR), where 
high-resolution imaging requires the use of an ER coil.  
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23Na MRI is not specific to cancerous lesions, that is, regions of low signal intensity (or 
TSC) are not necessarily regions of normal tissue and regions of high signal intensity are 
not necessarily cancerous lesions. 23Na MRI could prove to be a valuable addition to 
mpMRI to characterize lesions but at this point is not specific enough to detect lesion and 
lesion boundaries, which could explain the variation of TSC with increasing Gleason 
Score. 
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Chapter 4 !
4 Discussion & Future Work 
4.1 Discussion !
4.1.1 Overview 
Sodium MRI is a non-proton (x-nucleus) contrast-agent-free imaging technique deriving 
image contrast from the density of endogenous 23Na ions in tissue. Using 23Na MRI, it 
was possible to quantify tissue sodium concentration in-vivo, which has been shown to be 
an indicator of cellular metabolism and membrane integrity (1). Two custom-built RF 
coils; an asymmetric transmit birdcage coil, and an ER receive coil, allowed for 
acquisition of MR signal from the 23Na nuclei. The TPS registration made it possible to 
compare gold-standard, whole-mount histopathology grading of PCa with the sodium 
contrast with a registration accuracy of a few millimetres. Using 23Na MRI, the first in-
man quantification of sodium levels in the cancerous prostate was reported here.   
4.1.2 Clarification 
All in-vivo sodium contrast derived in this study was from endogenous 23Na nuclei. No 
introduction of sodium by oral or intravenous routes or any other contrast agent was 
required. As a result, the imaging period was not limited by agent wash-in/washout 
kinetics, nor was any approval required for contrast agent administration. 
The data analysis was categorized into PZ and CTZ to account for the differences in 
biologic functions, genetics, and prognoses between zones (2–4). Due to these 
differences, generalizations cannot be made about the whole prostate, only within zones. 
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It should also be noted that T2-w contrast alone is non-specific to PCa in the PZ and can 
also result from other low-intensity lesions such as scarring, hyperplasia, and prostatitis 
(5). PCa mpMRI exams may benefit from a complementary contrast such as 23Na MRI, 
which is specific to PCa. 
4.1.3 Clinical Significance 
At this juncture, we have been able to image, quantify and accurately co-register TSC 
with histopathological findings for three men with PCa. All three of these cases showed a 
significant positive trend of increased TSC with Gleason Score. This finding is in 
agreement with the literature of both brain and breast cancers, where there was an 
increase in observed TSC in malignant tissue when compared to normal contralateral 
tissue (6,7). As shown in Figure 6, normal PZ tissue had a lower TSC, when compared 
with the progressively aggressive scores of PIN, Gleason 3, Gleason 3+4, Gleason 3+5, 
Gleason 4+3, and Gleason 4. Of further importance, was the significance between lesions 
with Gleason Score 3+4 and Gleason Score 4+3 (Figure 6). According to the NCCN and 
CCO, this threshold is of critical value; any patient with a Score of 3+4 or less (≤ 3+4) 
should be placed in active surveillance, while patients with a Score of 4+3 or greater (≥ 
4+3) should undergo immediate treatment (8,9).  
A recent review of low-risk PCa in Canada concluded that the heath care system could 
save as much as $100 million annually by correctly stratifying PCa patients in 
appropriate treatment schemes (10). The savings were attributed to avoiding treatment in 
patients who died from causes other than PCa (treatment not required) and patients still 
receiving active surveillance. Not only would proper treatment planning alleviate the 
economic burden of overdiagnosis, the benefits are also apparent in the quality of life of 
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patients. Even taking into consideration the clinical discomfort of treatment as well as the 
psychological burden of active surveillance, a patient’s quality-adjusted life expectancy 
(QALE) is higher in patients who undergo active surveillance (QALE = 11.07) when 
compared to brachytherapy (QALE = 10.57), intensity-modulated radiotherapy (QALE = 
10.51), and radical prostatectomy (QALE = 10.23) (11).  
A practical limitation of 23Na MRI at this time is the requirement of a multinuclear MR 
scanner with the corresponding specialized hardware. While not every MRI system is 
capable of detecting nuclei other than protons, existing systems could be upgraded for 
this capability. Multinuclear MRI systems are also becoming more common in hospitals 
in recent years (12). 
4.2  Future Work 
4.2.1 Twisted Projection Imaging 
Twisted Projection Imaging (TPI) has the benefit of reducing the number of excitations 
(NEX) needed for a complete 3D image, therefore reducing the overall scan time. When 
acquiring signal in the frequency domain (k-space) TPI uses a series of spiral gradient 
trajectories, programed onto corresponding cones of differing angles that cover one 
hemisphere of k-space. This technique allows for more efficient sampling of the higher 
frequencies that are responsible for image detail, while preserving the lower spatial 
frequencies that are responsible for general shape and overall image contrast (13). TPI 
has been used successfully in assessment of stroke (14), cardiac tissue (15), and brain 
cancer (6). Implementing TPI imaging for 23Na MRI could substantially increase SNR 
affording reduced imaging scan (~10 min.) and/or increased resolution for this contrast. 
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4.2.2 RF Hardware Improvements 
The current study utilized an ER probe to receive sodium signal from the prostate and 
surrounding tissues, which led to the need for sensitivity correction of data for 
homogenous coverage over the prostate. The ER probe contains a single loop surface 
coil, resonating at the Larmor frequency of 23Na nuclei at 3T. An inhomogeneous receive 
profile whose sensitivity drops off rapidly with distance from the coil loop is an inherent 
property of a surface coil. An external 23Na tuned, non-rigid RF receive array coil, 
integrated with the existing transmit RF hardware would have the potential to produce a 
more homogeneous sodium contrast over the entire prostate. The array coil would be 
placed directly onto the pelvis of the patient to increase the penetration depth of imaging. 
Unfortunately, non-rigid array coils are subject to geometrical changes with patient 
anatomy and may require RF tuning on a per-patient basis, particularly due to the low 
gyromagnetic ratio of the 23Na nucleus. Evaluation of the receive sensitivity for such an 
arrangement would also require further investigation. 
The single-tuned nature of the 23Na ER probe required the sequential insertion of two 
probes (23Na and 1H), which is uncomfortable for the patient, and a time-consuming 
intermediary step. The use of a dual-tuned 23Na/1H ER probe would shorten total exam 
time and improve the overall patient experience. As mentioned above (3.2), a dual-tuned 
ER probe was initially developed, which was resonant at both sodium (23Na) and proton 
(1H) frequencies but its sensitivity at the sodium frequency was inferior to a sodium-only 
ER RF coil. Therefore, the dual-tuned ER coil was not used for this preliminary study; 
however, in future work, the advantages of such a coil may out-weigh the SNR penalty 
when one considers its benefits for image registration and patient comfort. 
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4.2.3 Additional MRI Contrast Comparisons 
This research has established that the integrated transmit-only, receive-only RF hardware 
developed by Farag et al. (16), is capable of accurately determining sodium levels in 
prostate cancer. More importantly, these measurements of TSC in prostate lesions have 
been directly compared with Gleason Score through a unique image registration pipeline. 
This pipeline can also be used to investigate the correlation of other mpMRI contrasts 
(T2-w, DCE, and ADC) with Gleason grading and compare it with these sodium results. 
Currently there are no comparisons of T2-w and ADC image contrasts with the gold 
standard of pathology. If 23Na MRI provided a significant advantage over current mpMRI 
contrast mechanisms in grading PCa, its utility within the clinic could be highlighted. The 
ability to distinguish between patients who should be placed in active surveillance and 
those who require immediate treatment shows great potential but requires further 
investigation.  
4.3 Conclusion 
This study highlighted the efficacy of in-vivo sodium magnetic resonance imaging for 
human prostate cancer. This thesis expanded on the work of Farag et al. (16) utilizing a 
23Na-tuned TORO RF coil system to image the prostate and translated the pre-clinical 
research of Bartha et al. (17) to non-invasively assess tissue sodium concentration in 
human prostate cancer. The purpose of this thesis was to examine the potential for the use 
of 23Na MRI in the clinic as a non-invasive tool to aid clinicians in PCa treatment 
stratification.! The sodium RF hardware was used to acquire quantitative endogenous 
sodium information, which is an indirect measure of cellular metabolism and integrity. 
The sodium contrast was registered to gold-standard Gleason Scores determined from 
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whole-mount histology, following radical prostatectomy. Analysis of these imaging data 
revealed a significant increase in TSC with increasing Gleason Score, as well as a 
significant difference between Gleason Scores 3+4 and 4+3. This distinction is of great 
importance because it is the threshold for defining treatment in the clinic. Prostate 
cancers with scores ≤ 3+4 are typically classified for active surveillance while scores ≥ 
4+3 are identified for immediate treatment. With further research, sodium MRI has the 
potential to become a complementary mpMRI contrast for non-invasive grading and 
active surveillance of this disease.  
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Appendix A – Supplementary Methods 
Multiparametric Proton MRI Protocol 
Patients were instructed to fast 12 hours prior to the exam, as well as drink 30 mL of milk 
of magnesia the night before. Upon arrival, patients were subjected to a screening exam 
to ensure all exclusion criteria had been followed. After screening, patients were escorted 
to the scanner bed, where all imaging took place. Calibration scans were acquired before 
introducing the 1H endorectal probe to locate the prostate. Xylocaine (2%) was applied as 
a topical anaesthetic before the insertion of the probe. After the 1H probe was introduced, 
two diffusion-weighted imaging (DWI) sequences were acquired with b-values of 100 
and 800 s·mm-2 to calculate an apparent diffusion coefficient (ADC) map; followed by a 
T2-weighted (T2-w) Cube ‘Master’ sequence; and a dynamic contrast-enhanced (DCE) 3D 
sequence. Imaging parameters from the three sequences can be found in Table 2.5.1. 
Following the mpMRI exam the 1H probe was removed and the patient was given a ten-
minute break before the sodium examination. 
Imaging Contrast 
Method 
TE/TR 
(ms) 
FOV 
(mm) 
Voxel Size 
(mm) 
Flip 
Angle 
Bandwidth 
 (KHz) 
Apparent Diffusion 
Coefficient MRI 
68.1/5600 140×140 1.1×0.55×3.6 90° 250 
Dynamic Contrast- 
Enhanced MRI 
1.54/3.1 100×140 0.78×1.1×3 12° 83.3 
T2-Weighted MRI 162/2000 140×140 0.44×0.73×1.4 90° 31.2 
Table A: Imaging parameters (TE/TR, FOV, Voxel Size, Flip Angle, and Bandwidth) of 
ADC, DCE and T2-w contrasts acquired in the mpMRI session. 
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Detailed Registration Steps 
2.7.1 Step 1 
The initial registration step in the pipeline (Figure 3.2.5.1a-b) involved a rigid 
registration between the 23Na volume and the 1H Axial T2-w volume, acquired serially. 
This registration step was necessary to correct for any motion that may have occurred 
between 23Na and 1H sequences. Fiducial points were fixed to the three reference 
calibration vials before a simple rotation/translation matrix was applied. 
2.7.2 Step 2 
The second step in the pipeline (Figure 3.2.5.1b-c) was the first non-rigid registration 
necessary due to the differing geometry between the 23Na and 1H endorectal probes. 
Fiducial points were identified in pairs on both the 1H axial T2-w volume and the 1H 
Master T2-w volume on ROIs, as described above.  
2.7.3 Step 3 
The third step in the pipeline (Figure 3.2.5.1f-c) utilized the non-rigid registration 
because of the deformation of tissue after radical prostatectomy. In this registration, the 
ex-vivo T2-w volume was the input image data that were deformed to the 1H Master T2-w 
reference. 
2.7.4 Step 4 
The fourth step (Figure 3.2.5.1e-f) did not require any registration techniques because 
both volumes involved (ex-vivo T1-w and ex-vivo T2-w), were acquired in the same 
imaging session without movement of the sample. 
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2.7.5 Step 5 
The fifth and final step (Figure 3.2.5.1d-e) registered the individual, digital whole mount 
histopathology images to the ex-vivo T1-w volume with sub-millimeter accuracy (18) by 
optimizing an affine transformation to minimize the fiducial registration error between 
the superficial and internal fiducial strands on MRI and the cross-sections of the fiducial 
strands on histology. Next, the TPS transformation was interactively defined to 
compensate for deformation between the ex-vivo and in-vivo MR images. 
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Appendix B – Hardware Approval 
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Appendix C – Human Participant Approval 
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Appendix D – Data Collection Form 
!!!!!!
Protocol IGPC-2                 Patient Initials:  ___ ___ ___   Study #: IGPC2-0 __ __ 
 
Multi-modality Prostate Cancer Image Guided Interventions 
CASE REPORT FORM 
Data Collection Form Version 4  Page 1 of 9 
Protocol Version 1.4 
 
 
 
Patient’s  DOB:  _______/_____/_____  (YYYY-MM-DD) 
 
Cohort:  □ Cohort 1 -Radical Prostatectomy      □ Cohort 2 -Prostate Biopsy 
 
Main Study Informed Consent 
□ Patient has read LOI  
□ Patient states understanding and all questions answered to their satisfaction  
□ Informed consent obtained, Date:  _______/_____/_____ 
□ Patient received copy of consent form 
 
Optional PET/MRI Imaging Informed Consent 
 
Did the patient agree to optional PET/MRI Imaging  □  No □  Yes 
If yes: 
Date informed consent obtained: _______/_____/_____ 
Consent version date: _______/_____/_____ 
 
Optional Na MRI Imaging Informed Consent 
 
Did the patient agree to optional Na MRI Imaging  □  No □  Yes 
If yes: 
Date informed consent obtained: _______/_____/_____ 
Consent version date: _______/_____/_____ 
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Protocol IGPC-2                 Patient Initials:  ___ ___ ___   Study #: IGPC2-0 __ __ 
 
Multi-modality Prostate Cancer Image Guided Interventions 
CASE REPORT FORM 
Data Collection Form Version 4  Page 2 of 9 
Protocol Version 1.4 
 
 
 
Limited Medical History 
 
 Yes No* 
Allergic reaction to Lidocaine gel (topical analgesic)   
Allergic reaction to Buscopan (anticholinergic/ system antispasmodic)   
Allergic reaction to Magnevist (contrast agent for MRI)   
Allergic reaction to iodine contrast  (contrast agent for Dynamic CT)   
Allergic reaction to 18F-Choline (radio-isotope for PET scan)   
Contraindications to Buscopan such as myasthenia gravis, untreated 
narrow angle glaucoma, prostatic hypertrophy with urinary retention, 
stenotic lesions of the gastrointestinal tract, tachycardia, angina, 
cardiac failure or megacolon 
  
Contraindications to MRI such as pacemaker or other electronic 
implants, known metal in the orbit, cerebral aneurysm clips or 
claustrophobia. 
  
*All answers must be 'no' to maintain eligibility. 
 
Imaging Requisitions: 
 PET/ CT Nuclear Medicine Requisition completed with patient 
 X-Ray Contrast Injection Patient Questionnaire 
 Robarts MRI Research Consent Form completed with patient 
*Please enter Robarts MRI Consent and X-ray Contrast Questionnaire into database. 
 
Patient instructed on MRI Prep:  
 30 mL of milk of magnesia night before  
 NPO prior to exam by 12 hours 
 
Patient instructed on PET/CT Prep: 
 Clear fluids only and nothing to eat 4 hours prior 
 250 mL water 30 minutes prior to exam 
 
 
Date Completed with patient: _____/_____/_____ (cannot be before consent date) 
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Protocol IGPC-2                 Patient Initials:  ___ ___ ___   Study #: IGPC2-0 __ __ 
 
Multi-modality Prostate Cancer Image Guided Interventions 
CASE REPORT FORM 
Data Collection Form Version 4  Page 3 of 9 
Protocol Version 1.4 
 
 
 
Eligibility Criteria 
 
Inclusion Criteria Yes No* 
Provision of informed consent for this study.   
Male, aged 18 years or older.   
Pathologically confirmed prostate cancer on previous biopsy.   
Suitable for and consenting to radical prostatectomy for treatment of 
prostate cancer, or repeat biopsy as standard of care. 
  
Exclusion Criteria Yes* No 
Prior therapy for prostate cancer (including hormone therapy), with the 
exception of radiation therapy for Cohort 2 only. 
  
Use of 5-alpha reductase inhibitors, i.e. finasteride (Proscar) or 
dutasteride (Avodart) within 6 months of study start.  Patients 
undergoing a 6-month washout period prior to study start will be eligible. 
  
Inability to comply with the pre-operative imaging panel.   
Patients scheduled for radical prostatectomy with prostate size 
exceeding dimensions for whole mount pathology slides. 
  
Allergy to contrast agents to be used as part of the imaging panel.   
Sickle cell disease or other anemias.   
Insufficient renal function (eGFR <60 ml/min/1.73m2).   
Residual bladder volume >150 cc (determined by post-void ultrasound).   
Hip prosthesis, vascular grafting or sources of artifact within the pelvis.   
Contraindication to MRI: 
o Pacemaker or other electronic implants 
o Known metal in the orbit 
o Cerebral aneurysm clips 
  
 *If any checkmarks appear in this column patient is ineligible. 
 
 
Is patient eligible to continue?      Yes    No 
 
 
Date of Eligibility Assessment:  _____/_____/_____ 
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Protocol IGPC-2                 Patient Initials:  ___ ___ ___   Study #: IGPC2-0 __ __ 
 
Multi-modality Prostate Cancer Image Guided Interventions 
CASE REPORT FORM 
Data Collection Form Version 4  Page 4 of 9 
Protocol Version 1.4 
 
 
 
Pre-Treatment Procedures  
 
Physical Exam including DRE   Date: _____/_____/_____ 
 
Pre-biopsy PSA    ______ ng/mL  Date: _____/_____/_____ 
 
Date of Diagnostic TRUS Biopsy  Date: _____/_____/____   (confirming prostate cancer) 
 
Prostate Volume (from TRUS Biopsy):    ______ cc 
 
Clinical Staging:      cT1a     cT1b     cT1c     cT2a     cT2b     cT2c 
Pathological Staging:  pT2a     pT2b     pT2c 
 
Screening Bloodwork 
 
Date of Tests: Date: _____/_____/_____  
Were all tests performed on the same day?    Yes    No 
Creatinine __________ µmol/L   
eGFR __________ ml/min/1.73m2  (must be > 60) 
Urea __________ mmol/L 
Sickle Cell Screen  Positive     Negative 
Date Post-Void Ultrasound Performed:  _____/_____/_____ 
Residual Bladder Volume:  _________ mL (must be <150 cc) 
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Protocol IGPC-2                 Patient Initials:  ___ ___ ___   Study #: IGPC2-0 __ __ 
 
Multi-modality Prostate Cancer Image Guided Interventions 
CASE REPORT FORM 
Data Collection Form Version 4  Page 5 of 9 
Protocol Version 1.4 
 
Pre-Operative Imaging Panel 
 
  Date of Scans 
YYYY-MM-DD 
Imaging Day 1    
 Dynamic CT/ 18F-FCH PET _____/_____/_____ 
 Optional PET/MRI   or   □N/A _____/_____/_____ 
Imaging Day  2    
 MRI (T1, T2, DWI, DCE, MRS)      _____/_____/_____ 
 3D TRUS _____/_____/_____ 
 Optional Na MRI    or   □N/A _____/_____/_____ 
   
Was entire imaging panel completed?       Yes    No 
If No, state reason: _________________________________________________ 
________________________________________________________________ 
 
Has all imaging been completed within a 2 week period?            Yes    No 
If No, state reason: _________________________________________________ 
________________________________________________________________ 
 
Has all imaging been completed within 6 weeks of RRP/ Biopsy?   Yes    No 
If No, state reason: _________________________________________________ 
________________________________________________________________  
 
PROCEDURE 
Cohort 1: Radical Prostatectomy 
Date _____/_____/_____ Time: _______   Location: _______  Surgeon: _________ 
Type of Surgery:       Open           Robotic Assisted Laparoscopic 
Please check all that are applicable: 
 Nerve Sparing     If yes, specify    Unilateral R or L   or    Bilateral  
 Non-nerve Sparing 
 Sural nerve graft 
Pelvic lymph node dissection performed? 
   Yes 
   No 
Cohort 2: Prostate Biopsy 
Date _____/_____/_____ Time: ______   Location: ______  Radiologist: _________ 
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Protocol IGPC-2                 Patient Initials:  ___ ___ ___   Study #: IGPC2-0 __ __ 
 
Multi-modality Prostate Cancer Image Guided Interventions 
CASE REPORT FORM 
Data Collection Form Version 4  Page 6 of 9 
Protocol Version 1.4 
 
Concomitant Medications / Treatments 
 
Record all medications/ supplements/ treatments taken within 2 weeks of study start 
and up to the day before Prostatectomy/ Prostate Biopsy. 
Medication/ 
Supplement Dose Unit Route Freq. Indication 
Start 
Date 
Stop 
Date 
 
 
     
 
 
 
 
 
 
 
     
 
 
 
 
 
        
 
 
     
 
 
 
 
 
 
 
     
 
 
 
 
 
        
        
        
        
        
        
        
        
        
        
        
 
 
 
CRA Completing CRF: ______________________________     Date Completed: _____/_____/_____ 
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Protocol IGPC-2                 Patient Initials:  ___ ___ ___   Study #: IGPC2-0 __ __ 
 
Multi-modality Prostate Cancer Image Guided Interventions 
CASE REPORT FORM 
Data Collection Form Version 4  Page 7 of 9 
Protocol Version 1.4 
 
 
18F-FCH PET/CT Scan 
 
Date of 18F-FCH PET/CT Scan: _____/_______/_____ 
 
Time of 18F-FCH Injection: ____:____              
 
Vital Sign Assessments Throughout 18F-FCH PET/CT Scan  
 Time Heart Rate (bpm) 
Oxygen 
Saturation (%) 
Blood Pressure 
(mmhg) 
Baseline (prior to 18F-
FCH injection) 
    
Post PET Scan     
 
Were venous samples collected?     Yes   Not Done 
If not done, reason: ___________________________________________________ 
 
Venous Sampling during 18F-FCH PET of Pelvis   
Sample # Sampling 
Time 
Check if 
Obtained If no, reason: 
1-18FCH Injection 0 sec   
2 20 sec   
3 40 sec   
4 60 sec   
5 2 min   
6 3 min   
7 4 min   
8 6 min   
9 8 min   
10 12 min   
11 16 min   
12 20 min   
13 24 min   
 
Did any adverse events occur during PET/CT scanning?    Yes   No 
If yes, record in AE log. 
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Protocol IGPC-2                 Patient Initials:  ___ ___ ___   Study #: IGPC2-0 __ __ 
 
Multi-modality Prostate Cancer Image Guided Interventions 
CASE REPORT FORM 
Data Collection Form Version 4  Page 8 of 9 
Protocol Version 1.4 
 
Optional PET/MRI Scan 
 
Consented to Optional PET/MRI?    Yes   No 
 
If Yes, Date of Optional PET/MRI Scan: _____/_______/_____  
 
Did any adverse events occur during PET/MRI scanning?    Yes   No 
If yes, record in AE log. 
 
Optional Na MRI Scan 
 
Consented to Optional Na MRI?     Yes   No 
 
If Yes, Date of Optional Na MRI Scan: _____/_______/_____  
 
Did any adverse events occur during Na MRI scanning?    Yes   No 
If yes, record in AE log. 
 
MRI/MRS Scan 
 
Date of MRI Scan: _____/_______/_____ 
 
Did any adverse events occur during MRI scanning?    Yes   No 
If yes, record in AE log. 
 
Was a 3D TRUS performed following the MRI?   Yes   No 
 
If no, reason: ______________________________________________________ 
 
_________________________________________________________________ 
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Protocol IGPC-2                 Patient Initials:  ___ ___ ___   Study #: IGPC2-0 __ __ 
 
Multi-modality Prostate Cancer Image Guided Interventions 
CASE REPORT FORM 
Data Collection Form Version 4  Page 9 of 9 
Protocol Version 1.4 
Adverse Events   
 
*AE reporting is restricted to the study period prior to Radical Prostatectomy or 
Biopsy (i.e. during imaging panel acquisition) as the Radical Prostatectomy and 
Biopsy are not considered part of the study intervention.    
    
Were there any adverse events?  No     Yes, complete below.  
 
Event Start Date Stop Date Causality Severity SAE Y / N Action Taken 
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 
 
 
CRF Completed By: _____________________        Date: ________________ 
 
Causality Severity Grade Action Taken 
1  Unrelated 1  Mild 1  No action taken 
2  Unlikely 2  Moderate 2  Medication taken 
3  Possible 3  Severe 3  Imaging delayed/ stop prematurely  
4  Probable 4  Life-threatening or disabling 4  Withdrawn from study 
5  Definite 5  Death 88  Other- specify  
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Appendix E – Curriculum Vitae ! JUSTIN!PETERSON!EDUCATION!!
M.Sc.!Medical!Biophysics!Candidate,!Western!University! !!!!!!!!!!!! ! !2013!T!Present!
• Specialization!in!Molecular!Imaging!
B.Sc.!(Hons)!Medical!Biophysics,!Western!University! ! !!!!!!!!!!!!!!!!!!!!2008!T!2012!
• Honours!Specialization!in!Medical!Biophysics!(Physical!Science!Concentration)!!AWARDS!!
• Western!Scholarship!of!Distinction:!! ! ! ! ! !!!!!!!!!!!!!!!!2008!
! Awarded!to!a!student!in!1st!year!with!an!average!from!87T89.9%.!!!RESEARCH!EXPERIENCE!!
• Undergraduate!Honours!Thesis!(supervised!by!Dr.!Blaine!Chronik):!“Investigating!the!effect!of!MR!induced!heating!around!passive!medical!implants!in!the!sagittal!plane.”!
• Undergraduate!SixTweek!Project!(supervised!by!Dr.!Blaine!Chronik):!“Radio!Frequency!Interactions!with!Medical!Devices.”!!VOLUNTEERING!!
Security!–!Palmer!Rapids!Twin!Music!Festival,!Palmer!Rapids,!ON2007!–!Present!
• Monitoring!over!3000!patrons!to!ensure!their!safety!and!the!success!of!the!event!!
Science!Games!Organizer!–!Science!Students’!Council,!UWO! ! !!!!!2009!–!2011!
• Organized!activities!that!provided!a!social!outlet!in!order!to!increase!community!and!pride!within!the!faculty!!PUBLICATIONS!!
• “Unshielded!Asymmetric!TransmitTOnly!and!Endorectal!ReceiveTOnly!Radiofrequency!Coil!for!23Na!MRI!of!the!Prostate!at!3!Tesla”,!Farag!A.,!Peterson!J.!et#al.,#J!Magn!Reson!Imaging,!(2014).!!
• “In*Vivo!Sodium!MRI!of!Prostate!Cancer:!Correlations!with!Gleason!Grade!Using!Whole!Mount!Pathology”,!Peterson!J.!et#al.,!Work!in!Progress.!!!CONFERENCE!PROCEEDINGS!!
• “In#Vivo!Sodium!Imaging!of!Human!Prostate!Cancer”,!Poster!Presenter,!London!Health!Research!Day,!(2015).!!
• “In#Vivo!Sodium!Imaging!of!Human!Prostate!Cancer”,!Poster!Presenter,!Oncology!Research!and!Education!Day,!(2015).!!
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• “In#Vivo!Sodium!MRI!of!Human!Prostate!Cancer”,!Oral!&!Poster!Presenter,!13th#Annual!Imaging!Network!Ontario!Symposium,!(2015).!!
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